Replimune Group, Inc. (REPL) Form 10-Q — Oct 28, 2026
Replimune filed its fiscal Q2 2027 10-Q reporting a net loss of $57.1 million ($0.54/share) for the quarter ended September 30, 2026, a 31% improvement from $83.1 million a year ago, driven by the April 2026 restructuring and post-approval cost discipline. The quarter's headline event was FDA accelerated approval of TUDRIQEV on August 6, 2026 for unresectable advanced cutaneous melanoma progressing on anti-PD-1 therapy. The launch began in early October 2026, with roughly 20 melanoma institutions already on formulary and over 15 having written prescriptions as of October 23, 2026.
Key figures
- Total Debt
- 99766000
- Total Assets
- 373940000
- Cash Position
- 307833000
- Shares Outstanding
- 94800404
- Ignyte orr
- 24.2%
- Q1 rd expense
- 34365000
- Q1 sga expense
- 21916000
- Accumulated deficit
- 1389406000
- Hercules tranche4 draw
- 15000000
- Q1 rd expense prior year
- 57877000
- Median duration of response
- 14.1 months
- Term loan principal balance
- 97882000
- August 2026 offering net proceeds
- 141000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.